Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

T 601

Next Previous
X
Search
Drug Profile

T 601

Alternative Names: T 6011; T601

Latest Information Update: 15 Jan 2020

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Transgene - Tasly Pharmaceutics Group (JV)
  • Developer Tasly Pharmaceuticals, Inc.
  • Class Antineoplastics; Gene-directed enzyme-prodrug therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action DNA synthesis inhibitors; Gene transference; Prodrug activators; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 20 Nov 2019 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Combination therapy, Second-line therapy or greater) in China (Parenteral, Injection) (NCT04226066)
  • 20 Nov 2019 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Monotherapy) in China (Parenteral, Injection) (NCT04226066)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top